

Literature Report

Reporter: yinzhu chen

Date: 2021-12-23



This article is made available via the [ACS COVID-19 subset](#) for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.



J|A|C|S
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

pubs.acs.org/JACS

Communication

Renal-Clearable Molecular Probe for Near-Infrared Fluorescence Imaging and Urinalysis of SARS-CoV-2

Si Si Liew,[†] Ziling Zeng,[†] Penghui Cheng, Shasha He, Chi Zhang, and Kanyi Pu*



Cite This: *J. Am. Chem. Soc.* 2021, 143, 18827–18831




Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



J. Am. Chem. Soc. 2021, 143, 18827–18831

Author Information




Associate Professor

Assistant Dean For Research, College of Engineering
School of Chemical & Biomedical Engineering
School of Physics and Mathematical Science
Lee Kong Chian School of Medicine
Nanyang Technological University

Education experience

2011-2015: Postdoc, Stanford University
2007-2011: PhD, National University of Singapore
2004-2007: MS, Fudan University
2000-2004: BSc, East China University of Sci & Tech

Kanyi Pu, PhD, FRSC



Molecular Imaging:

在分子水平上检测和监测疾病微环境中的病理过程，发展无创高通量药物筛选技术，主要是药物代谢的实时体内成像和药物诱导的毒性变化。


Nanotechnology:

开发具有最先进成像方式的有机半导体纳米材料，如光声成像、近红外荧光成像和生物发光成像，以提高成像穿透深度和空间分辨率。

Probe Design

设计和合成可激活的成像探针，揭示如活性自由基如何调节肿瘤代谢、促进转移和血管生成，并促进耐药表型等过程。

Introduction



现有临床诊断:

(1) 抗原检测、IgM/IgG抗体检测、ELISA

特点:

可区分既往感染和现行感染。但是这些诊断方法是静态的，不能区分活病毒/非活病毒或反映病毒复制活性

(2) RT-PCR: 检测SARS-CoV-2核糖核酸来检测病毒复制活性

特点:

高灵敏度和选择性。

突变会增加检测的假阴性结果。

对于无症状、轻度症状，低病毒载量可能不足以进行qRT-PCR检测


新型检测技术:

(3) 由生物标志物激活信号的荧光分子探针

SARS-COV-2 Mpro



The coronavirus virion and life cycle.




SARS-COV-2 Mpro :
 新冠病毒多肽复制加工
 过程中的主要蛋白酶
 Mpro, 又称3CLPro

SARS-COV-2 Mpro



Coronavirus polyprotein processing and non-structural proteins



nsp1 Host mRNA degradation, translation inhibition

nsp2 Unknown

nsp3 Polyprotein processing, de-ADP-ribosylation, deubiquitination, interferon antagonist, DMV formation

nsp4 DMV formation

nsp5 Polyprotein processing, inhibition of interferon signalling

nsp6 DMV formation

nsp7 Cofactor for RNA-dependent RNA polymerase

nsp8 Primase or 3'-terminal adenylyltransferase, cofactor for RNA-dependent RNA polymerase

nsp9 Binding of single-stranded RNA

nsp10 Cofactor for nsp14 and 16

nsp11 Unknown

nsp12 RNA-dependent RNA polymerase, nucleotidyltransferase



nsp13 Helicase, RNA 5' triphosphatase

nsp14 3' to 5' exoribonuclease, proofreading, RNA cap formation, guanosine N7-methyltransferase

nsp15 Endoribonuclease, evasion of immune response

nsp16 RNA cap formation, ribose 2'-O-methyltransferase


Probe design strategy




Probe design strategy




a Hepatobiliary clearance



b Renal clearance



Cyclodextrin (HP β CD)



Probe design strategy





Figure 5. Representative HNAPs for liver injury models. Blue moiety






Figure 3. Representative HNAPs for inflammation models. Blue moiety represents the responsive unit.




Synthetic Procedures




SARS(Trt)

SARS(Trt)-PABA

SARS(Trt)-Br




三氟乙酸




SARS-Cy

SARS(Trt)-Cy





In vitro characterization of SARS-CyCD




(1)体外表征其光学特性， HPLC证明 SARS-CyCD成功裂解

(2)酶促反应动力学研究证明酶与底物具有较高亲和力


(3)SARS-CyCD与多种不同类型的蛋白酶反应， 证明酶促反应的特异性

The pharmacokinetics of SARS-CyCD



结论:


- (1) CyCD的消除速度和消除半衰期均快于SARS-CyCD
- (2) CyCD的肾脏清除率高于SARS-CyCD.




- (3) 尿液中排出的SARS-CyCD的荧光增强可以忽略不计, 证明SARS-CyCD在活小鼠体内的代谢很少
- (4) 解剖小鼠发现体内少量残留的SARS-CyCD全部聚集在肺部(16%), 肝脏(14%) 和肾脏(5%),



In vivo detection of SARS-COV-2



细胞毒性检测



NIH3T3Cell

- (1) 证明基于SARS-CyCD的光学尿液分析特异性检测SARS-COV2感染的可行性。
- (2) SARS-CyCD具有较好的生物相容性。



Summary



内容:

(1) 提供了第一个能够实时、无创原位成像和尿检 SARS-CoV-2感染的荧光探针

(2) 由于该探针可以检测病毒蛋白酶，这种方法有可能在感染过程中直接监测病毒的复制活动，

创新:

在于体内原位成像及SARS-CyCD首次通过光学尿液分析检测SARS-COV-2感染的应用

展望:

SARS-CyCD可在呼吸机、气雾剂或便携式喷雾器的帮助下进一步发展成气雾喷剂，允许通过吸入给药。因此，SARS-CyCD可能代表了新一代基于吸入的covid-19尿液检测方法

